ino-6145
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2018 (NCT03606213)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03606213 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2018 | Inovio Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles, University of California, San Francisco |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2018 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2018 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1